Gastric mucosa prostaglandin secretion

“Gastric mucosa prostaglandin secretion” is not a single molecular target or receptor but refers to the physiological process by which prostaglandins (primarily Prostaglandin E2/PGE2) are produced and released by cells in the gastric mucosa. Prostaglandins play a critical role in regulating gastric acid secretion, stimulating mucus and bicarbonate secretion, maintaining mucosal blood flow, and providing protection against a variety of mucosal injuries. Deficiency in mucosal prostaglandins is associated with increased risk of peptic ulcers and gastric injury, especially in the setting of NSAID use. Therapeutically, prostaglandin analogs are used to augment mucosal defense and inhibit acid secretion in ulcer management, while NSAIDs can impair this protective mechanism by inhibiting prostaglandin synthesis[1][2][3][4][5]. Note: This entry is incorrect as a target because “Gastric mucosa prostaglandin secretion” describes a process rather than a distinct receptor, protein, or molecule amenable to direct pharmacological targeting. The relevant molecular targets would be specific prostaglandin receptors (such as EP3, EP4) or the enzymes involved in prostaglandin biosynthesis (e.g., cyclooxygenase-1/COX-1, prostaglandin E synthase).

Other names

Prostaglandin E2 gastric secretionGastric mucosal prostaglandinGastric prostaglandin synthesis

Inhibition of gastric acid secretion via prostaglandin receptors (primarily EP3 and EP4), enhancement of mucus and bicarbonate secretion, and modulation of mucosal blood flow.